Podcasts about sigilon therapeutics

In this episode, we speak with Devyn Smith, the CEO of Arbor Biotechnologies, which is an early stage life sciences company pushing the boundaries of biodiscovery.  Arbor has raised over $200 million dollars and is backed by Temasek and other notable investors. Devyn also serves as Chairman of the Alliance for Regenerative Medicine (ARM) and advises multiple biotech companies. Previously, he was Chief Operations Officer and Head of Strategy at Sigilon Therapeutics, a clinical stage biotechnology company, and before that he was Head of Operations and Strategy, Medicinal Sciences at Pfizer. Arbor's platform employs a diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – for accelerating the discovery of proteins for improving human health and sustainability. I am your host RJ Lumba.  We hope you enjoy the show.  If you like the episode, click to subscribe.

En este episodio de Carreras Científicas Alternativas, entrevistamos a Amalia Capilla. Amalia es directora de Terapia Celular para Diabetes en Sigilon Therapeutics. En esta entrevista nos habla de su recorrido profesional, y nos explica como todos los grandes saltos, cambios de dirección, e incluso parones durante su carrera, la han llevado siempre a un lugar mejor que el anterior, hasta acabar encontrando su lugar. Nos anima a no tener miedo y ser valientes para perseguir lo que queremos... porque el que la sigue, la consigue.Si quieres dar el paso a reorientarte profesionalmente, visita nuestra web https://carrerascientificasalternativas.com y descubre de qué modos podemos ayudarte a conseguirlo.

Dr. Paul K. Wotton is the Chief Executive Officer at Obsidian Therapeutics. Obsidian is a biotechnology company pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE™ technology provides a way to control protein degradation using FDA-approved small molecules, permitting precise control of the timing and level of protein expression. The cytoDRiVE™ platform can be applied to design controllable intracellular, membrane and secreted proteins for cell and gene therapies as well as other applications. The Company’s initial applications focus on developing novel cell therapies for the treatment of cancer. Paul has over 30 years of experience in scientific research, product development and corporate growth in the life science industry. Previously, Paul served as Founding President and Chief Executive Officer of Sigilon Therapeutics, Inc. Prior to Sigilon, Dr. Wotton served as President and Chief Executive Officer of Ocata Therapeutics until its acquisition by Astellas Pharma where he was also Co-Chairman of the Office of Integration. In previous roles, Paul has served as President and Chief Executive Officer of Antares Pharma (NASDAQ:ATRS) as well as Chief Executive Officer of Topigen Pharmaceuticals. Dr. Wotton is a named inventor on numerous patents and was the Ernst & Young Entrepreneur of the Year Regional (NJ) Winner Life Sciences in 2014. He serves on the Boards of Directors of Vericel Corporation (NASDAQ: VCEL) and Cynata Therapeutics (ASX: CYP) as its Chairman. Until recently Paul was a board member at Veloxis Pharmaceuticals A/S (Copenhagen: VELO) which was recently acquired by Asahi. Dr. Wotton holds a B.Pharm (Honors) from UCL, London’s global university, and a Ph.D. in Pharmaceutical Sciences from University of Nottingham.

There are a number of rare disease where a genetic mutation results in the deficiency of an enzyme or other critical protein that can lead to a progressive or life-threatening condition. Patients have been treated with the chronic administration of recombinant versions of the proteins they lack. While this provides benefit, it requires regular infusions or self-administered shots, is costly, and disruptive. Sigilon is developing what it calls “Shielded Living Therapeutics,” encased cells that can be implanted to provide steady levels of the protein a patient lacks and free them from the need for constant administration of these biologics. We spoke to Rogerio Vivaldi, president and CEO of Sigilon Therapeutics, about the company’s living therapeutics, how it’s able to protect these cells from attack from the immune system, and how they function once inside the body.

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Novo Nordisk, MolMed, Orchard Therapeutics, Gsk, Astrazaneca, Recordati, Mylan, Orphan Europe, Eli Lilly, Sigilon Therapeutics, Farmindustria, AveXis, Novartis, Leo Pharma Italia Persone: Lorenzo Wittum (Astrazaneca Italia), Eugenio Aringhieri (Farmindustria)Nuove terapie: Cisteamina bitartratoPatologie: Cistinosi nefropatica, diabete, atrofia muscolare spinale (SMA), psoriasi, tumori testa-collo.Lavoro: Clinical Trial Associate, Clinical Research Associate Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Novo Nordisk, MolMed, Orchard Therapeutics, Gsk, Astrazaneca, Recordati, Mylan, Orphan Europe, Eli Lilly, Sigilon Therapeutics, Farmindustria, AveXis, Novartis, Leo Pharma Italia Persone: Lorenzo Wittum (Astrazaneca Italia), Eugenio Aringhieri (Farmindustria)Nuove terapie: Cisteamina bitartratoPatologie: Cistinosi nefropatica, diabete, atrofia muscolare spinale (SMA), psoriasi, tumori testa-collo.Lavoro: Clinical Trial Associate, Clinical Research Associate Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

Today in FirstWord:

Michelle Maskaly and Christen Harm talk to Devyn Smith, chief strategy officer and head of operations for Sigilon Therapeutics on the topic of pharma's reputation, both in the US and Europe. Leadership Tip from Devyn Smith.

In this podcast, we interviewed Dr. Paul Wotton, CEO, about Sigilon Therapeutics’ discovery platform. The platform combines cell engineering and biocompatible Afibromer™ technology to enable cell therapies that do not trigger fibrosis View show notes at cellculturedish.com/novel-technology-enables-encapsulated-cell-therapeutics-without-triggering-fibrosis/